Investigational Site Number : 1240023

Calgary, Alberta T3A 2N1

1 studies enrolling now · 2 studies all time

What they study most

Dermatitis Atopic

Studies at this site

• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials — Enrolling by invitation
• A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo — Completed